Mounjaro, a newer medication, contains tirzepatide, which works similarly to GLP-1 but also activates GIP receptors, resulting in enhanced weight loss
Important Notes : Dual hormone pathway activation differentiates it from GLP-1-only medications
Canada Europe Germany UK France Spain Italy Switzerland Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa South Africa Saudi Arabia Rest of Middle East & Africa Table of Contents Chapter 1 Methodology & Scope Chapter 2 Executive Summary Chapter 3 Industry Insights Chapter 4 Competitive Landscape, 2022 Chapter 5 Market Estimates and Forecast, By Drug Class (USD Million) Chapter 6 Market Estimates and Forecast, By Route of Administration (USD Million) Chapter 7 Market Estimates and Forecast, By Application (USD Million) Chapter 8 Market Estimates and Forecast, By Distribution Channel (USD Million) Chapter 9 Market Estimates and Forecast, By Region (USD Million) Chapter 10 Company Profiles Don't see your key competitors
Takeaway: When appetite is suppressed by GLP-1 medications, hitting protein targets requires deliberate planning and often supplementation
Last updated: 05/15/2026 North Florida residents can now access doctor-supervised GLP-1 weight loss treatment with Tirzepatide (Mounjaro) through convenient telehealth appointments
